{"id":"W3004966554","doi":"10.1200/jco.2020.38.5_suppl.tps65","title":"SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Internal medicine; Mucosal melanoma; Adjuvant therapy; Clinical endpoint; Oncology; Clinical trial; Adjuvant; Phases of clinical research; Surgery; Gastroenterology; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782263,0.001824972,0.001281498,0.0004338531,0.0003491342,0.001059009,0.0009442128,0.001106765,0.005910349],"category_scores_gemma":[0.0008299347,0.0005527093,0.00157374,0.0002899899,0.001148178,0.0007105786,0.0004455613,0.002304662,0.001358179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007723748,"about_ca_system_score_gemma":0.002285919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000995948,"about_ca_topic_score_gemma":0.002779491,"domain_scores_codex":[0.9996141,0.0001875876,0.00001390522,0.00004920748,0.00004761072,0.00008755341],"domain_scores_gemma":[0.9993756,0.0000620502,0.000131933,0.00004771008,0.00002806997,0.0003546246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8583998,0.04320425,0.004318066,0.001098907,0.001251764,0.0002111488,0.0002767523,0.001564319,0.02775547,0.0004525953,0.004605057,0.0568618],"study_design_scores_gemma":[0.6716661,0.3147932,0.006010632,0.0000480312,0.0004044259,0.0001702792,0.00006127462,0.0007477003,0.002205128,0.0002264334,0.003647316,0.00001955819],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861288,0.002785509,0.0009799481,0.0008732446,0.0002833089,0.004201868,0.00161384,0.000201677,0.002931861],"genre_scores_gemma":[0.9692721,0.003330223,0.003079813,0.001399794,0.0003630102,0.008974218,0.003860133,0.00007788109,0.009642826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005910349,"threshold_uncertainty_score":0.01977205,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1982378803464021,"score_gpt":0.4882958499286043,"score_spread":0.2900579695822022,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}